News and blogs
169 results found.
Blood cancer drug Tepkinly authorised for use on NHS
The drug for diffuse large B-cell lymphoma, Tepkinly, has been authorised for use on the NHS as a third line treatment.
From despair to hope: The Matthew Wilson Multiple Myeloma Fund
Matthew Wilson establishes the Matthew Wilson Multiple Myeloma Fund (MWMMF) at Blood Cancer UK.
Research links childhood CT scan exposure to increased blood cancer risk
In new research, scientists have linked increased CT scan exposure to an increased risk of blood cancer in younger people.
How our research gave vaccine answers to people with blood cancer
Read about how our scientists were able to understand the effectiveness of the COVID-19 vaccine for clinically extremely vulnerable people.
The stolen legacy of Henrietta Lacks
Taken without her knowledge, Henrietta's 'immortal' cells have had an everlasting impact on research and medical ethics.
New non-Hodgkin lymphoma drug
A drug for non-Hodgkin lymphoma, epcoritamab, has been authorised for use in the UK for adults.
Zanabrutinib recommended for adults with CLL in the UK
Zanubrutinib has been recommended for adults with the blood cancer, chronic lymphocytic leukaemia (CLL) in England.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
What we can achieve with £1 million
We're proud to announce We’ve invested over £1 million funding five research projects, across five different blood cancers
The story of Dr Jane C Wright, pioneer of blood cancer research
To mark the start of Black History Month, we share the story of Dr Jane C Wright, a true pioneer in the field of blood cancer research
The father of the blood bank - Charles R. Drew
For Black History Month, we are celebrating Charles R. Drew who was an African American surgeon and researcher who pioneered in the field of blood transfusions, blood storage and created the first blood banks.
Myeloma drug approved for use
A new treatment for those with the blood cancer myeloma has been approved for use by NICE. It could benefit thousands.
Ruxolitinib approved for treatment of polycythaemia vera in England and Wales
The drug, ruxolitinib, has been recommended for use by NICE to treat the blood cancer polycythaemia vera in those whose disease is resistant or intolerant to the treatments hydroxycarbamide/hydroxyurea.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
National Cancer Research Institute to close.
Blood Cancer UK's Sarah McDonald said it's sad that this long-standing, multi-partner collaboration is winding down.
Blood Cancer UK have renewed their partnership with RareCan
Blood Cancer UK have renewed their partnership with RareCan, a digital health company. This could give people an opportunity to help researchers.
A new dawn for clinical trials
A new dawn for clinical trials to get us to a place where no lives are lost to blood cancer
Targeting tumour stroma could improve immunotherapy response in lymphoma
Blood Cancer UK researchers at King's College London have shown how specific cells known as ‘fibroblast cells’ in lymphoma tumours suppress the body’s immune cells and immunotherapy treatment.
Blood cancer drug ruxolitinib gives better outcomes than those on best-available existing medication
The drug, ruxolitinib, has been found to be better at treating the blood cancer - polycythaemia vera (PV) than the best currently available treatment.
Using motixafortide to treat multiple myeloma
New research suggests that motixafortide improves stem cell transplants for those with multiple myeloma.
